CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Report for D003139: Common Cold NIH

(Synonyms: Common Cold)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (14)

Name (Synonyms) Correlation
drug401 Hydroxychloroquine, Doxycycline Wiki 0.71
drug399 Hydroxychloroquine, Clindamycin, Primaquine - high dose. Wiki 0.71
drug430 Interferon-Alpha2B Wiki 0.71
drug400 Hydroxychloroquine, Clindamycin, Primaquine - low dose. Wiki 0.71
drug210 ColdZyme® mouth spray Wiki 0.71
drug228 Convalescent Serum Wiki 0.71
drug397 Hydroxychloroquine, Azithromycin Wiki 0.71
drug398 Hydroxychloroquine, Clindamycin Wiki 0.71
drug230 Convalescent plasma Wiki 0.35
drug480 Losartan Wiki 0.27
drug507 Methylprednisolone Wiki 0.25
drug691 Remdesivir Wiki 0.21
drug854 Tocilizumab Wiki 0.18
drug616 Placebo Wiki 0.07

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.41
D008173 Lung Diseases, Obstructive NIH 0.35
D012141 Respiratory Tract Infections NIH 0.18
D003141 Communicable Diseases NIH 0.08
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Induced Rhinovirus Upper Respiratory Tract Infection in Healthy Volunteers. A Double-blind, Randomized, Placebo-controlled Study

This study evaluates the performance of ColdZyme® mouth spray on prevention and alleviation of induced rhinovirus upper respiratory tract infection in healthy volunteers. Half of participants will receive ColdZyme® mouth spray while the other half will receive placebo.

NCT02522949 Common Cold Device: ColdZyme® mouth spray Device: Placebo
MeSH:Common Cold

Primary Outcomes

Description: Reduction in viral load in the URT(Upper Respiratory Tract), after challenge with rhinovirus, in relation to placebo

Measure: Reduction in viral load in the URT

Time: 7 days

Secondary Outcomes

Description: Reduction of number of days having a total symptom severity score of 6 or higher using a 5-graded Jackson scale, in relation to placebo.

Measure: Prevention of symptomatic URTI (Upper Respiratory Tract Infection)

Time: 11 days

Description: Asymptomatic URTI will be assessed by quantification of viral load at peak day (day with highest viral load measured by oropharyngeal swab).

Measure: Prevention of asymptomatic URTI.

Time: 11 days

Description: The number of days with cold is defined as the sum of all days with a total score of ≥ 6 according to the modified method of Jackson.

Measure: Fewer days with symptomatic URTI

Time: 11 days

Description: The number of days with asymptomatic URTI is defined as the sum of all days with a viral load significantly different from the baseline.

Measure: Fewer days with asymptomatic URTI.

Time: 11 days

Description: Nasal samples will be analysed for the quantity of IL-6 (Interleukin 6), IL-8 and IFNα (Interferon alpha).

Measure: Lower level of proinflammatory proteins

Time: 11 days

Measure: Lower daily total symptom score

Time: 11 days

Measure: Lower daily score of individual symptoms

Time: 11 days

2 Audio Data Collection for Identification and Classification of Coughing

An open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.

NCT04326309 COVID-19 Coronavirus Infections Hay Fever Asthma Chronic Obstructive Pulmonary Disease Influenza Common Cold Respiratory Tract Infections Healthy
MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Common Cold Severe Acute Respiratory Syndrome Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive
HPO:Chronic obstructive pulmonary disease Obstructive lung disease Respiratory tract infection

Primary Outcomes

Description: Size of collected audio dataset measured as number of collected cough sounds, targeting ≥10,000 identified coughs.

Measure: Dataset size

Time: 14 days

Secondary Outcomes

Description: Identification of cough sounds by the existing mathematical model with ≥ 99% specificity and ≥ 60% sensitivity

Measure: Cough sound identification

Time: 14 days

Description: Increase in the sensitivity of the mathematical model to cough sounds to ≥ 70% while retaining the specificity of ≥ 99%

Measure: Improvement of the existing model

Time: 14 days

Description: Determination of the level of acceptance and satisfaction of the solution by patients by means of a Standard Usability Questionnaire to provide feedback. The score ranges from 10 to 50, higher score indicating a better usability.

Measure: Evaluate the usability of the application

Time: 14 days

HPO Nodes